PharmaEssentia Corp
PharmaEssentia Corp., a leading biopharmaceutical company headquartered in Taiwan (TW), is dedicated to the development and commercialisation of innovative therapies for patients with rare diseases. Founded in 2003, the company has made significant strides in the industry, particularly in the fields of haematology and oncology. PharmaEssentia's flagship product, a novel treatment for essential thrombocythemia, exemplifies its commitment to addressing unmet medical needs with unique, scientifically-backed solutions. With a strong presence in Asia and expanding operations in global markets, PharmaEssentia has established itself as a key player in the biopharmaceutical landscape, recognised for its rigorous research and development efforts. The company continues to focus on delivering high-quality, effective therapies that improve patient outcomes and enhance quality of life.
DitchCarbon Score
How does PharmaEssentia Corp's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PharmaEssentia Corp's score of 24 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
PharmaEssentia Corp's reported carbon emissions
In 2023, PharmaEssentia Corp reported total carbon emissions of approximately 4,374,400 kg CO2e, with Scope 2 emissions from purchased electricity accounting for about 2,905,970 kg CO2e. This marks a slight increase from 2022, when total emissions were about 4,264,600 kg CO2e, with Scope 2 emissions at approximately 3,037,270 kg CO2e. The company has not disclosed any Scope 1 emissions data, and there is no reported Scope 3 emissions data for 2023. PharmaEssentia has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction targets suggests a need for further commitment to climate action within the pharmaceutical industry context. The emissions data is not cascaded from any parent organization, indicating that PharmaEssentia Corp is independently reporting its emissions. The company continues to monitor its carbon footprint, but further transparency and commitment to reduction strategies would enhance its climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - |
| Scope 2 | 3,055,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 669,860 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PharmaEssentia Corp is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
